Prophylactic use of factor VIII: An economic evaluation

Thrombosis and Haemostasis

Volumn 79, Issue 5, 1998, Pages 932-937

  Bohn, Rhonda L ^a,c   Avorn, Jerry ^a   Glynn, Robert J ^a   Choodnovskiy, Igor ^a   Haschemeyer, Rudy ^b   Aledort, Louis M ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8;

ABSENTEEISM; ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISABILITY; DRUG USE; HEALTH CARE COST; HEMOPHILIA; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL;

EID: 0031955272     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615097     Document Type: Article

References (35)

1. Rosendaal FR, Varekamp I, Smith C, Brocker-Vriends AHJT, van Dijck H, Vandenbroucke JP, Hermans J, Suurmeijer TPBM, Briet E. Mortality and causes of death in Dutch hemophiliacs, 1973-1986. Br J Haematology 1989; 71: 71-6.
2. Ross-Degnan D, Soumerai SB, Avorn J, Bohn RL, Bright R, Aledort LM. Hemophilia home treatment. Economic analysis and implications for health policy. 1995 Int J Technol Assess Health Care;11(2): 327-44.
3. Bona RD, Weinstein RA, Weisman SJ, Bartolomeo A, Rickles FR. The use of continuous infusion of factor concentrates in the treatment of hemophilia. Am J Hematol 1989; 32: 8-13.
4. Martinowitz U, Schulman S, Gitel S, Horozowski H, Heim M, Varon D. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Br J Haematology 1992; 82: 729-34.
5. Ahlberg A. Hemophilia in Sweden. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Ortho Scan 1965; 77 Suppl; 5-99.
6. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Int Med 1992; 232: 2225-32.
7. Lusher JM. Prophylaxis in children with hemophilia: Is it optimal treatment? Thromb Haemost 1997; 78: 726-9.
8. Shanbrom E, Thelin GM. Experimental prophylaxis of severe hemophilia with a factor VIII concentrate. JAMA 1969; 208(10): 1853-6.
9. Aledort LM. Prophylaxis: the next haemophilia treatment. J Int Med 1992; 232: 1-2.
10. van Creveld, S. Prophylaxis of joint hemorrhages in hemophilia. Acta Haemat 1971; 45: 120-7.
11. Petterson H, Nilsson IM, Hedner U, Norehn K, Ahlberg A. Radiologic evaluation of prophylaxis in severe haemophilia. Acta Paediatr Scand 1981; 70: 565-70.
12. Aronstam A, Arblaster PG, Rainsford SG, Turk P, Slattery M, Alderson MR, Hall DE, Kirk PJ. Prophylaxis in haemophilia: A double-blind controlled trial. Br J Hemat 1976; 33: 81-90.
13. Editorial. Prophylaxis in haemophilia. Lancet 1971; 705(1): 917.
14. Editorial. Hemophilia prophylaxis. JAMA 1970; 212(13): 2256-7.
15. Smith PS, Teutsch SM, Shaffer PA, Rolka H, Evatt B. Episodic versus prophylactic infusions for hemophilia A: A cost-effectiveness analysis. J Pediatr 1996; 129: 424-31.
16. Kasper CK, Dietrich SL, Rapaport SI. Hemophilia prophylaxis with factor VIII concentrate. Arch Intern Med 1970; 125: 1004-9.
17. Petrini P, Lindvall N, Egberg N, Blomback M. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Ped Hematology/Oncology 1991; 13(3): 280-7.
18. Nilsson IM, Hedner U, Ahlberg A. Hemophilia prophylaxis in Sweden. Acta Paediatr Scand 1976; 65: 129-35.
19. Ramsay DM, Parker AC. A trial of prophylactic replacement therapy in haemophilia and Christmas disease. J Clin Path 1973; 26: 243-7.
20. Linney DR, Lazerson J. Hemophilia: Cost considerations for prescribing therapeutic materials. Transfusion 1979; 19: 57-9.
21. Smith PS, Keyes NC, Forman EN. Socioeconomic evaluation of a state-funded comprehensive hemophilia-care program. N Engl J Med 1982; 306: 575-9.
22. Robinson PM, Tittley P, Smiley RK. Prophylactic therapy in classical hemophilia: a preliminary report. Canad Med Ass J 1976; 97(11): 559-6.
23. Aledort LM, Haschemeyer RH, Pettersson H. A longitudinal study of orthopedic outcomes for severe factor VIII deficient hemophiliacs. J Int Med (October) 1994; 236(4): 391-9.
24. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. 1992 J Int Med; 232(1): 25-32.
25. Pettersson H, Gilbert M. Musculoskeletal and other haemorrhagic complications. In Diagnostic Imaging in Hemophilia. Berlin: Springer-Verlag 1985: 55-60.
26. Employment and Earnings. U.S. Department of Labor, Bureau of Labor Statistics. 1991-1992.
27. Computer-Assisted Hospitalization Analysis for the Study of Efficacy (CHASE). Brigham and Women's Hospital, Boston, MA. 1992.
28. Medical Economics Data. Red Book. 1992 Medical Economics Inc., Montvale, NJ.
29. McCullagh P. Regression models for ordinal data (with discussion). 1980 J Roy Statist Soc B; 42: 109-42.
30. SAS Institute Inc: The LOGISTIC Procedure, in SAS/STAT User's Guide. Release 6.03 ed, Gary, NC, SAS Institute, 1988.
31. Lipsitz DR, Harrington DP. Analyzing correlated binary data using SAS. Comput Biomed Res 1990; 23: 268-82.
32. Martinowitz U, Schulman S, Gitel S, Horozowski H, Heim M, Varon D. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Br J Haematol 1992; 82(4): 729-34.
33. Schulman S, Varon D, Keller N, Gitel S, Martinowitz U. Monoclonal purified F VIII for continuous infusion: stability, microbiological safety and clinical experience. Thromb Haemost 1994; 72(3): 403-7.
34. Aledort LM, Bohn RL. Prophylaxis and continuous infusion for hemophilia: can we afford it? Blood Coagul Fibrinolysis 1996; 7 Suppl 1: S35-S7.
35. Bjorkman S, Carlsson M, Berntorp E, Stenberg P. Pharmacokinetics of factor VIII in humans. Clin Pharmacokinetics. 1992; 22: 385-95.